The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
NMDA Antagonist Neurotoxicity: Mechanism and Prevention
Abstract
Antagonists of the N-methyl-D-aspartate (NMDA) subtype of glutamate receptor, including phencyclidine (PCP) and ketamine, protect against brain damage in neurological disorders such as stroke. However, these agents have psychotomimetic properties in humans and morphologically damage neurons in the cerebral cortex of rats. It is now shown that the morphological damage can be prevented by certain anticholinergic drugs or by diazepam and barbiturates, which act at the γ-aminobutyric acid (GABA) receptor-channel complex and are known to suppress the psychotomimetic symptoms caused by ketamine. Thus, it may be possible to prevent the unwanted side effects of NMDA antagonists, thereby enhancing their utility as neuroprotective drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glutamate neurotoxicity and diseases of the nervous system
CHOI, D. (1988) · Neuron · doi:10.1016/0896-6273(88)90162-6 · Cited by 7,972
Pathological Changes Induced in Cerebrocortical Neurons by Phencyclidine and Related Drugs
Olney, J. W., Labruyere, J., & Price, M. T. (1989) · Science · doi:10.1126/science.2660263 · Cited by 1,237
Self-citationSynaptic release of excitatory amino acid neurotransmitter mediates anoxic neuronal death
Rothman, S. (1984) · The Journal of Neuroscience · doi:10.1523/jneurosci.04-07-01884.1984 · Cited by 884
Ketamine: an update on the first twenty-five years of clinical experience
Reich, D. L., & Silvay, G. (1989) · Canadian Journal of Anaesthesia · doi:10.1007/bf03011442 · Cited by 708
Study, R. E., & Barker, J. L. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.11.7180 · Cited by 561
Excitatory amino acids and neuropsychiatrie disorders
Olney, J. W. (1989) · Biological Psychiatry · doi:10.1016/0006-3223(89)90072-3 · Cited by 322
Self-citationMacdonald, R. L., & Barker, J. L. (1978) · Science · doi:10.1126/science.205953 · Cited by 177
The anti-excitotoxic effects of certain anesthetics, analgesics and sedative-hypnotics
Olney, J. W., Price, M. T., Fuller, T. A., Labruyere, J., Samson, L., Carpenter, M., & Mahan, K. (1986) · Neuroscience Letters · doi:10.1016/0304-3940(86)90224-7 · Cited by 150
Self-citationLevitan, E. S., Blair, L. A. C., Dionne, V. E., & Barnard, E. A. (1988) · Neuron · doi:10.1016/0896-6273(88)90125-0 · Cited by 131
Phencyclidine, Dizocilpine, and Cerebrocortical Neurons
Allen, H. L., & Iversen, L. L. (1990) · Science · doi:10.1126/science.2403696 · Cited by 130
Cited by
Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease
Minoshima, S., Giordani, B., Berent, S., Frey, K. A., Foster, N. L., & Kuhl, D. E. (1997) · Annals of Neurology · doi:10.1002/ana.410420114 · Cited by 1,802
Glutamate receptor dysfunction and schizophrenia
Olney, J. W. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950240016004 · Cited by 1,685
Self-citationJentsch, J. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00060-8 · Cited by 1,314
Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms
Zanos, P., Moaddel, R., Morris, P. J., Riggs, L. M., Highland, J. N., Georgiou, P., Pereira, E. F. R., Albuquerque, E. X., Thomas, C. J., Zarate, C. A., et al. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.015198 · Cited by 1,260
Excitotoxicity and stroke: Identifying novel targets for neuroprotection
Lai, T. W., Zhang, S., & Wang, Y. T. (2014) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2013.11.006 · Cited by 1,106
NMDA receptor hypofunction model of schizophrenia
Olney, J. W., Newcomer, J. W., & Farber, N. B. (1999) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(99)00029-1 · Cited by 1,020
Self-citationSchmued, L. C., Albertson, C., & Slikker, W. (1997) · Brain Research · doi:10.1016/s0006-8993(96)01387-x · Cited by 994
White Matter Changes in Schizophrenia: Evidence for Myelin-Related Dysfunction
Davis, K. L., Stewart, D. G., Friedman, J. I., Buchsbaum, M., Harvey, P. D., Hof, P. R., Buxbaum, J., & Haroutunian, V. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.5.443 · Cited by 793
Murrough, J. W., Perez, A. M., Pillemer, S., Stern, J., Parides, M. K., aan het Rot, M., Collins, K. A., Mathew, S. J., Charney, D. S., & Iosifescu, D. V. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.06.022 · Cited by 786
Ketamine Pharmacology: An Update ( Pharmacodynamics and Molecular Aspects, Recent Findings )
Mion, G., & Villevieille, T. (2013) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12099 · Cited by 711
Nitrous oxide (laughing gas) is an NMDA antagonist, neuroprotectant and neurotoxin
Jevtović-Todorović, V., Todorovć, S. M., Mennerick, S., Powell, S., Dikranian, K., Benshoff, N., Zorumski, C. F., & Olney, J. W. (1998) · Nature Medicine · doi:10.1038/nm0498-460 · Cited by 676
Self-citationKetamine: A Review of Clinical Pharmacokinetics and Pharmacodynamics in Anesthesia and Pain Therapy
Peltoniemi, M. A., Hagelberg, N. M., Olkkola, K. T., & Saari, T. I. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0383-6 · Cited by 672
Danysz, W., & Parsons, C. G. (1998) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01382-6 · Cited by 649
Ketamine: Teaching an Old Drug New Tricks
Kohrs, R., & Durieux, M. E. (1998) · Anesthesia & Analgesia · doi:10.1097/00000539-199811000-00039 · Cited by 604
Glutamatergic mechanisms in schizophrenia
Tsai, G., & Coyle, J. T. (2002) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.42.082701.160735 · Cited by 577
Steele, R. J., & Morris, R. G. M. (1999) · Hippocampus · doi:10.1002/(sici)1098-1063(1999)9:2<118::aid-hipo4>3.0.co;2-8 · Cited by 561
Excitotoxicity and the NMDA receptor -- still lethal after eight years
Rothman, S. (1995) · Trends in Neurosciences · doi:10.1016/0166-2236(95)93869-y · Cited by 508
Clinical Experience With Excitatory Amino Acid Antagonist Drugs
Muir, K. W., & Lees, K. R. (1995) · Stroke · doi:10.1161/01.str.26.3.503 · Cited by 502
Targeting glutamate signalling in depression: progress and prospects
Murrough, J. W., Abdallah, C. G., & Mathew, S. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.16 · Cited by 482
NMDA-dependent modulation of CA1 local circuit inhibition
Grunze, H., Rainnie, D., Hasselmo, M., Barkai, E., Hearn, E., McCarley, R., & Greene, R. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-06-02034.1996 · Cited by 467
“Although systemic exposure to NMDA antagonists does not result in sufficient disinhibition to elicit epileptiform activity (Javitt and Zukin, 1991; Krystal et al., 1994), Olney et al. (1991) have suggested that it is sufficient in at least the retrosplenial and posterior cingulate region of the limbic cortex to evoke…”
BackgroundSigtermans, M. J., van Hilten, J. J., Bauer, M. C. R., Arbous, S. M., Marinus, J., Sarton, E. Y., & Dahan, A. (2009) · Pain · doi:10.1016/j.pain.2009.06.023 · Cited by 467
Vollenweider, F. (1997) · Neuropsychopharmacology · doi:10.1016/s0893-133x(96)00246-1 · Cited by 444
Glutamate: its role in learning, memory, and the aging brain
McEntee, W. J., & Crook, T. H. (1993) · Psychopharmacology · doi:10.1007/bf02253527 · Cited by 403
Vollenweider, F. X., Leenders, K. L., Scharfetter, C., Antonini, A., Maguire, P., Missimer, J., & Angst, J. (1997) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(96)00039-9 · Cited by 353
Behavior and Development in Children and Age at the Time of First Anesthetic Exposure
Kalkman, C. J., Peelen, L., Moons, K. G., Veenhuizen, M., Bruens, M., Sinnema, G., & de Jong, T. P. (2009) · Anesthesiology · doi:10.1097/aln.0b013e31819c7124 · Cited by 349
A systems model of altered consciousness: integrating natural and drug-induced psychoses
Vollenweider, F. X., & Geyer, M. A. (2001) · Brain Research Bulletin · doi:10.1016/s0361-9230(01)00646-3 · Cited by 343
Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment
Konradi, C., & Heckers, S. (2003) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00328-5 · Cited by 336
Models of schizophrenia in humans and animals based on inhibition of NMDA receptors
Bubeníková-Valešová, V., Horáček, J., Vrajová, M., & Höschl, C. (2008) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2008.03.012 · Cited by 336
MATTSON, M. P., & SCHEFF, S. W. (1994) · Journal of Neurotrauma · doi:10.1089/neu.1994.11.3 · Cited by 309
Ellison, G. (1995) · Brain Research Reviews · doi:10.1016/0165-0173(94)00014-g · Cited by 303
Acute and chronic effects of ketamine upon human memory: a review
Morgan, C. J. A., & Curran, H. V. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0572-3 · Cited by 302
NMDA receptors and memory encoding
Morris, R. G. M. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.04.014 · Cited by 295
Drug‐induced Apoptotic Neurodegeneration in the Developing Brain
Olney, J. W., Wozniak, D. F., Jevtovic‐Todorovic, V., Farber, N. B., Bittigau, P., & Ikonomidou, C. (2002) · Brain Pathology · doi:10.1111/j.1750-3639.2002.tb00467.x · Cited by 298
Self-citationCalpain inhibition: an overview of its therapeutic potential
Wang, K. K. W., & Po-Wai, Y. (1994) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(94)90090-6 · Cited by 274
Prolonged seizures and cellular injury: Understanding the connection
Fujikawa, D. G. (2005) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2005.08.003 · Cited by 273
Correll, G. E., Maleki, J., Gracely, E. J., Muir, J. J., & Harbut, R. E. (2004) · Pain Medicine · doi:10.1111/j.1526-4637.2004.04043.x · Cited by 271
Kaczmarek, L., & Chaudhuri, A. (1997) · Brain Research Reviews · doi:10.1016/s0165-0173(97)00005-2 · Cited by 267
Cellular and Molecular Pathways of Ischemic Neuronal Death
Won, S.-J., Kim, D.-Y., & Gwag, B.-J. (2002) · BMB Reports · doi:10.5483/bmbrep.2002.35.1.067 · Cited by 260
Ketamine: NMDA Receptors and Beyond
Zorumski, C. F., Izumi, Y., & Mennerick, S. (2016) · The Journal of Neuroscience · doi:10.1523/jneurosci.1547-16.2016 · Cited by 254
Network beyond IDO in psychiatric disorders: Revisiting neurodegeneration hypothesis
Myint, A.-M., & Kim, Y.-K. (2014) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.08.008 · Cited by 230
Glutamatergic model psychoses: prediction error, learning, and inference
Corlett, P. R., Honey, G. D., Krystal, J. H., & Fletcher, P. C. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2010.163 · Cited by 229
Neuroprotective effects of the green tea components theanine and catechins
Kakuda, T. (2002) · Biological & Pharmaceutical Bulletin · doi:10.1248/bpb.25.1513 · Cited by 165
Baseline gamma power during auditory steady-state stimulation in schizophrenia
M. Spencer, K. (2012) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2011.00190 · Cited by 155
Mechanisms of Action and Persistent Neuroplasticity by Drugs of Abuse
Korpi, E. R., den Hollander, B., Farooq, U., Vashchinkina, E., Rajkumar, R., Nutt, D. J., Hyytiä, P., & Dawe, G. S. (2015) · Pharmacological Reviews · doi:10.1124/pr.115.010967 · Cited by 148
Dextromethorphan: An update on its utility for neurological and neuropsychiatric disorders
Nguyen, L., Thomas, K. L., Lucke-Wold, B. P., Cavendish, J. Z., Crowe, M. S., & Matsumoto, R. R. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.01.016 · Cited by 141
Ampuero, E., Rubio, F. J., Falcon, R., Sandoval, M., Diaz-Veliz, G., Gonzalez, R. E., Earle, N., Dagnino-Subiabre, A., Aboitiz, F., Orrego, F., et al. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.04.035 · Cited by 132
Effects of Subanesthetic Ketamine on Regional Cerebral Glucose Metabolism in Humans
Långsjö, J. W., Salmi, E., Kaisti, K. K., Aalto, S., Hinkka, S., Aantaa, R., Oikonen, V., Viljanen, T., Kurki, T., Silvanto, M., et al. (2004) · Anesthesiology · doi:10.1097/00000542-200405000-00006 · Cited by 123
Decreased glutamate + glutamine in Alzheimer’s disease detected in vivo with 1 H-MRS at 0.5 T
Antuono, P. G., Jones, J. L., Wang, Y., & Li, S.-J. (2001) · Neurology · doi:10.1212/wnl.56.6.737 · Cited by 119
L-Lactate protects neurons against excitotoxicity: implication of an ATP-mediated signaling cascade
Jourdain, P., Allaman, I., Rothenfusser, K., Fiumelli, H., Marquet, P., & Magistretti, P. J. (2016) · Scientific Reports · doi:10.1038/srep21250 · Cited by 116
Kawamata, J., & Shimohama, S. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-110173 · Cited by 111
Lewén, A., Li, G. L., Olsson, Y., & Hillered, L. (1996) · Brain Research · doi:10.1016/0006-8993(96)00081-9 · Cited by 90
Timofeeva, O. A., & Levin, E. D. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.08.038 · Cited by 74
“1), presumably, as a result of neuronal disinhibition (Olney et al., 1991; Grunze et al., 1996; Greene, 2001; Newcomer and Krystal, 2001), despite the fact that the density of NMDAR located on principal cells is significantly higher than on”
BackgroundEgerton, A., Fusar-Poli, P., & M. Stone, J. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212799316244 · Cited by 36
Has psychiatry tamed the “ketamine tiger?” Considerations on its use for depression and anxiety
Rasmussen, K. G. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.01.002 · Cited by 32
Bettini, E., Stahl, S. M., De Martin, S., Mattarei, A., Sgrignani, J., Carignani, C., Nola, S., Locatelli, P., Pappagallo, M., Inturrisi, C. E., et al. (2022) · Pharmaceuticals · doi:10.3390/ph15080997 · Cited by 31
Ketamine: stimulating antidepressant treatment?
Malhi, G. S., Byrow, Y., Cassidy, F., Cipriani, A., Demyttenaere, K., Frye, M. A., Gitlin, M., Kennedy, S. H., Ketter, T. A., Lam, R. W., et al. (2016) · BJPsych Open · doi:10.1192/bjpo.bp.116.002923 · Cited by 29
Metadata
- Authors
- Olney, J. W., Labruyere, J., Wang, G., Wozniak, D. F., Price, M. T., & Sesma, M. A.
- Venue
- Science
- Published
- 1991-12-06
- Volume
- 254
- Issue
- 5037
- Pages
- 1515-1518
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2021099633
- Cited by
- 841
- References
- 16
- FWCI
- 9.50
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.